276 related articles for article (PubMed ID: 24102406)
1. Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target.
Allocca M; Jovani M; Fiorino G; Schreiber S; Danese S
Curr Drug Targets; 2013 Nov; 14(12):1508-21. PubMed ID: 24102406
[TBL] [Abstract][Full Text] [Related]
2. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside.
Jovani M; Fiorino G; Danese S
Curr Drug Targets; 2013 Nov; 14(12):1444-52. PubMed ID: 23746199
[TBL] [Abstract][Full Text] [Related]
4. Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance.
Mudter J; Neurath MF
Inflamm Bowel Dis; 2007 Aug; 13(8):1016-23. PubMed ID: 17476678
[TBL] [Abstract][Full Text] [Related]
5. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?
Zhang Z; Hinrichs DJ; Lu H; Chen H; Zhong W; Kolls JK
Int Immunopharmacol; 2007 Apr; 7(4):409-16. PubMed ID: 17321463
[TBL] [Abstract][Full Text] [Related]
6. IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid.
Rafa H; Saoula H; Belkhelfa M; Medjeber O; Soufli I; Toumi R; de Launoit Y; Moralès O; Nakmouche M; Delhem N; Touil-Boukoffa C
J Interferon Cytokine Res; 2013 Jul; 33(7):355-68. PubMed ID: 23472658
[TBL] [Abstract][Full Text] [Related]
7. IL-23 in inflammatory bowel diseases and colon cancer.
Neurath MF
Cytokine Growth Factor Rev; 2019 Feb; 45():1-8. PubMed ID: 30563755
[TBL] [Abstract][Full Text] [Related]
8. Experimental immunomodulatory therapy of inflammatory bowel disease.
Schreiber S
Neth J Med; 1998 Dec; 53(6):S24-31. PubMed ID: 9883011
[TBL] [Abstract][Full Text] [Related]
9. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis.
Rath T; Billmeier U; Waldner MJ; Atreya R; Neurath MF
Arch Toxicol; 2015 Apr; 89(4):541-54. PubMed ID: 25632846
[TBL] [Abstract][Full Text] [Related]
10. Innate and adaptive immunity in inflammatory bowel disease.
Geremia A; Biancheri P; Allan P; Corazza GR; Di Sabatino A
Autoimmun Rev; 2014 Jan; 13(1):3-10. PubMed ID: 23774107
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Rose-John S; Mitsuyama K; Matsumoto S; Thaiss WM; Scheller J
Curr Pharm Des; 2009; 15(18):2095-103. PubMed ID: 19519447
[TBL] [Abstract][Full Text] [Related]
12. Cytokine and anti-cytokine therapies for inflammatory bowel disease.
Ogata H; Hibi T
Curr Pharm Des; 2003; 9(14):1107-13. PubMed ID: 12769750
[TBL] [Abstract][Full Text] [Related]
13. Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel disease.
Sato T; Kanai T; Watanabe M; Sakuraba A; Okamoto S; Nakai T; Okazawa A; Inoue N; Totsuka T; Yamazaki M; Kroczek RA; Fukushima T; Ishii H; Hibi T
Gastroenterology; 2004 Mar; 126(3):829-39. PubMed ID: 14988837
[TBL] [Abstract][Full Text] [Related]
14. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
[TBL] [Abstract][Full Text] [Related]
15. Emerging immunological targets in inflammatory bowel disease.
Monteleone G; Pallone F; MacDonald TT
Curr Opin Pharmacol; 2011 Dec; 11(6):640-5. PubMed ID: 22000933
[TBL] [Abstract][Full Text] [Related]
16. The pentacyclic triterpene Lupeol switches M1 macrophages to M2 and ameliorates experimental inflammatory bowel disease.
Zhu Y; Li X; Chen J; Chen T; Shi Z; Lei M; Zhang Y; Bai P; Li Y; Fei X
Int Immunopharmacol; 2016 Jan; 30():74-84. PubMed ID: 26655877
[TBL] [Abstract][Full Text] [Related]
17. Peripheral cytokine profile in Chilean patients with Crohn's disease and ulcerative colitis.
Beltrán CJ; Candia E; Erranz B; Figueroa C; Gonzalez MJ; Quera R; Hermoso MA
Eur Cytokine Netw; 2009 Mar; 20(1):33-8. PubMed ID: 19318319
[TBL] [Abstract][Full Text] [Related]
18. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
[TBL] [Abstract][Full Text] [Related]
19. Cytokines in inflammatory bowel disease.
Kmieć Z
Arch Immunol Ther Exp (Warsz); 1998; 46(3):143-55. PubMed ID: 9704146
[TBL] [Abstract][Full Text] [Related]
20. Role of Inflammation in the Development of Colorectal Cancer.
Muthusami S; Ramachandran IK; Babu KN; Krishnamoorthy S; Guruswamy A; Queimado L; Chaudhuri G; Ramachandran I
Endocr Metab Immune Disord Drug Targets; 2021; 21(1):77-90. PubMed ID: 32901590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
